1. Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (2018) Kommission Mamma. Diagnostik und Therapie von Patientinnen mit primärem und metastasiertem Brustkrebs—Empfehlungen der AGO Kommission Mamma.
https://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/Gesamt_deutsch/Alle_aktuellen_Empfehlungen_2018.pdf
. Accessed 04 June 2018
2. Saad ED, Katz A (2009) Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 20(3):460–464
3. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26(12):1987–1992
4. U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2007) Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.
https://www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf
. Accessed 26 July 2018
5. European Medicines Agency (EMA) (2018) Guideline on the evaluation of anticancer medicinal products in man 2017.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/11/WC500238764.pdf
. Accessed 26 July 2018